Status:
TERMINATED
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effectiv...
Eligibility Criteria
Inclusion
- Male and female subjects, 18 to 70 years of age, inclusive
- Treatment-naive OR subjects (prior relapsers) may be included who did not achieve sustained viral response 24 weeks after last planned dose of study drug (SVR24) after at least 1 prior course of Peg-IFN/RBV therapy of standard duration and had a documented undetectable HCV RNA level at the planned end of treatment of at least 42-week duration
- Subjects have IL28B CC genotype determined during screening
- Subjects have genotype 1 chronic hepatitis C and laboratory evidence of HCV infection for at least 6 months, defined by (1) documented HCV serology test at least 6 months before the first screening visit demonstrating the presence of anti-HCV antibody, or (2) documented presence of HCV RNA by a sensitive and specific assay at least 6 months before the first screening visit, or (3) documented histologic evidence of chronic hepatitis C demonstrated by fibrosis on a standardized histologic grading system at least 6 months before the first screening visit. If only inflammation is present in the liver histologic report, then 6 months of laboratory evidence is required
Exclusion
- Subjects have received previous treatment with telaprevir or any other protease inhibitor(s) for chronic hepatitis C
- Subjects who did not achieve SVR24 after at least 1 prior course of Peg-IFN/RBV therapy of standard duration and never achieved undetectable HCV RNA while on treatment
- Subjects have evidence of hepatic decompensation
- Subjects have evidence of cirrhosis
- Subjects have diagnosed or suspected hepatocellular carcinoma
- Subjects have any other cause of significant liver disease in addition to hepatitis C, which may include but is not limited to malignancy with hepatic involvement, hepatitis B, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, nonalcoholic steatohepatitis, or primary biliary cirrhosis. Steatosis is allowed if clinically asymptomatic
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
239 Patients enrolled
Trial Details
Trial ID
NCT01459913
Start Date
November 1 2011
End Date
January 1 2014
Last Update
June 10 2015
Active Locations (83)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35209
2
Birmingham, Alabama, United States, 35294
3
Phoenix, Arizona, United States, 85054
4
La Jolla, California, United States, 93037